在新加坡，同源和异源疫苗加强针与 COVID-19 发病率和严重程度的关联。
Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore.
机构信息
Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Ministry of Health, Singapore.
出版信息
JAMA. 2022 Mar 22;327(12):1181-1182. doi: 10.1001/jama.2022.1922.
Abstract
This study estimates SARS-CoV-2 infections and disease severity with the receipt of a booster and by type of booster.
摘要
这项研究估计了加强针的接种和加强针类型对 SARS-CoV-2 感染和疾病严重程度的影响。
相似文献
1
Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore.在新加坡，同源和异源疫苗加强针与 COVID-19 发病率和严重程度的关联。
JAMA. 2022 Mar 22;327(12):1181-1182. doi: 10.1001/jama.2022.1922.
2
Studies Suggest COVID-19 Vaccine Boosters Save Lives.研究表明，新冠疫苗加强针可挽救生命。
JAMA. 2022 Jan 11;327(2):115. doi: 10.1001/jama.2021.23455.
3
Israel's high case plateau may offer worrisome portent.以色列居高不下的病例数可能预示着令人担忧的情况。
Science. 2021 Sep 24;373(6562):1428-1429. doi: 10.1126/science.acx9161. Epub 2021 Sep 23.
4
Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans.同源或异源新冠病毒加强针在退伍军人中的有效性。
N Engl J Med. 2022 Apr 7;386(14):1375-1377. doi: 10.1056/NEJMc2200415. Epub 2022 Feb 9.
5
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.ChAdOx1-S 和 BNT162b2 或 mRNA-1273 疫苗异源初免和加强接种的安全性：全国队列研究。
BMJ. 2022 Jul 13;378:e070483. doi: 10.1136/bmj-2022-070483.
6
Audio Interview: Covid-19 as an Endemic Disease.音频访谈：作为一种地方病的新冠疫情。
N Engl J Med. 2022 Feb 10;386(6):e21. doi: 10.1056/NEJMe2201982.
7
Scientists see a 'really, really tough winter' with Omicron.科学家们认为，随着奥密克戎毒株的出现，将会迎来一个“极其艰难的冬天”。
Science. 2021 Dec 17;374(6574):1421-1422. doi: 10.1126/science.acz9834. Epub 2021 Dec 16.
8
SARS-CoV-2 vaccine boosters: The time to act is now.SARS-CoV-2 疫苗加强针：现在是行动的时候了。
PLoS Med. 2021 Dec 9;18(12):e1003882. doi: 10.1371/journal.pmed.1003882. eCollection 2021 Dec.
9
Audio Interview: A New Look at Covid-19 Vaccine Boosters.音频访谈：对新冠疫苗加强针的新审视
N Engl J Med. 2021 Oct 21;385(17):e72. doi: 10.1056/NEJMe2116820.
10
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用：来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
引用本文的文献
1
Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial.雾化Ad5-nCoV新冠疫苗在一项非劣效性随机对照试验中的安全性、有效性和免疫原性
NPJ Vaccines. 2024 Oct 31;9(1):209. doi: 10.1038/s41541-024-01003-x.
2
National epidemiological analysis of the association of COVID-19 vaccination and incidence of COVID-19 cases in Canada, January to August 2021.2021年1月至8月加拿大COVID-19疫苗接种与COVID-19病例发生率关联的全国性流行病学分析。
Can Commun Dis Rep. 2023 Apr 1;49(4):145-154. doi: 10.14745/ccdr.v49i04a07.
3
Editorial: COVID-19 booster vaccination: increasing immunity against life-threatening infection.社论：新冠病毒加强针接种：增强对危及生命感染的免疫力
Front Public Health. 2024 Jan 9;11:1342118. doi: 10.3389/fpubh.2023.1342118. eCollection 2023.
4
Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates.在非人灵长类动物中，用大猩猩腺病毒（GRAd）S-2P疫苗在上呼吸道和下呼吸道均实现了对SARS-CoV-2的持久免疫。
bioRxiv. 2023 Nov 22:2023.11.22.567930. doi: 10.1101/2023.11.22.567930.
5
SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review.老年人中的 SARS-CoV-2 疫苗突破性感染：荟萃分析和系统评价。
BMC Infect Dis. 2023 Sep 4;23(1):577. doi: 10.1186/s12879-023-08553-w.
6
Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses.在北欧国家奥密克戎为主导期间，不同异源第三剂疫苗接种方案对严重 COVID-19 的效果比较：基于人群的队列分析。
BMJ. 2023 Jul 24;382:e074325. doi: 10.1136/bmj-2022-074325.
7
mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals.mRNA-1273 加强针接种后，在未感染过 SARS-CoV-2 的个体和 COVID-19 康复者中产生了可比的 SARS-CoV-2 特异性功能应答。
Front Immunol. 2023 Apr 21;14:1136029. doi: 10.3389/fimmu.2023.1136029. eCollection 2023.
8
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.KD-414 新冠灭活疫苗在成年人中的单剂加强免疫的免疫原性和安全性：日本一项开放标签、单中心、非随机、对照研究。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2193074. doi: 10.1080/21645515.2023.2193074. Epub 2023 Apr 13.
9
Nosocomial SARS-CoV-2 transmission in multi-bedded hospital cubicles over successive pandemic waves: Lower mortality but wider spread with Omicron despite enhanced infection-prevention measures.多床位医院隔离间中 SARS-CoV-2 的医院内传播：尽管采取了强化感染预防措施，但与 Omicron 相比，连续的大流行波中的病死率降低，但传播范围更广。
Infect Dis Health. 2023 May;28(2):81-87. doi: 10.1016/j.idh.2022.09.003. Epub 2022 Oct 7.
10
Evaluation of a point of care lateral flow assay for antibody detection following SARS CoV-2 mRNA vaccine series.评估一种基于即时检测的侧向流动测定法，用于检测 SARS CoV-2 mRNA 疫苗系列接种后的抗体。
J Immunol Methods. 2023 Feb;513:113410. doi: 10.1016/j.jim.2022.113410. Epub 2022 Dec 29.
Zotero 插件